INVESTORS
Overview
Fact Sheet
Analyst Coverage
Corporate Presentations
Recent Filings
Stock Price
Home
Investors
Contact
About
Welcome
Mission
Partnering
Patents
A.I. Platform
Our Technology
RADR
®
Collaborations
Pipeline
Overview
LP300 | LP184 | LP284 |ADC Program
Clinical Trials
Compassionate Use
Publications
Posters
TEAM
Leadership
Board of Directors
Advisors
Lantern Careers
MEDIA
News
Podcasts
Press
Social Media
Newsletter
Videos
Webinars
Contact
Investors
News
Lantern Pharma aims to take drug to phase 3 for $100-200 million with AI-powered approach
← Back to Media
InNovate with us
Partner with us
Learn more about partnering
Join our Mailing List to get the latest Lantern news, sent right to your inbox
Never spam. Unsubscribe anytime.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
